Search results
-
ESMO 2025 preview – Enhertu's early breast hat-trick
… vs chemo + Herceptin + Perjeta Data presented at ASCO 2025; PDUFA date 23 Jan 2026 LBA18 …
- 05/19/2026 - 19:49 -
Zelgen’s DLL3 trispecific goes pivotal
… Suzhou Zelgen China ph2 data in 3rd-line SCLC at ASCO 2025: ORR 63% & 58% with 10mg & 30mg respectively; ph3 …
- 05/19/2026 - 19:49 -
Joyo starts its first pivotal trial
… x CD8 fusion protein, in relapsed cervical cancer. At ASCO 2025 the company reported two partial responses in this …
- 05/19/2026 - 19:49 -
J&J goes straight into phase 3 in prostate
… T-cell engager, possibly because phase 1 data presented at ASCO 2025 suggested that pasritamig could offer a safer … or chemo Pasritamig, uncontrolled Data presented at ASCO 2025 Source: OncologyPipeline & …
- 05/19/2026 - 19:49 -
World Lung 2025 – Ideaya challenges Zai Lab
… ph1 Presentation venue World Lung 2025 ASCO 2025 ORR* 72% (52/72)** 51% (38/74)^ …
- 05/19/2026 - 19:49 -
Novocure’s Lunar eclipse
… + Abraxane, vs gemcitabine + Abraxane Data at ASCO 2025: OS 16.2mth vs 14.2mths; filed with FDA Aug 2025, …
- 05/19/2026 - 19:49 -
BioNTech quietly drops Claudin6 work
… Ph1/2 in solid tumours Disappointing results at ASCO 2025 BNT315 (GEN1055)* Ox40 agonist Hexabody …
- 05/19/2026 - 19:49 -
No starring role for GSK’s Tim-3
… + LB4330 (anti-Claudin18.2/CD8 fusion protein); ORR 50% at ASCO 2025 BC3402 Tim-3 MAb BioCity Biopharma …
- 05/19/2026 - 19:49 -
Sino takes out the rest of Merck’s partner
… (LM-108) Anti-CCR8 MAb Pooled ph1/2 data at ASCO 2025: 18% ORR (13/74) in pancreatic cancer + anti-PD-1; …
- 05/19/2026 - 19:49 -
AbbVie steps up for Glenmark's multispecific
… T-cell engager Global ph1 Trignite-1 ; data at ASCO 2025 Unnamed Cellyan Therapeutics …
- 05/19/2026 - 19:49
